STAR
STAR Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
0 of 3 strong
The short version
Strides aims to grow its U.S. Strides Pharma Science expects steady revenue growth driven by diversified businesses, particularly strong momentum in Ex-US markets. - Operational EBIT margin was maintained around 18.2% despite geopolitical and cost pressures. - Operational PAT grew 8% year-on-year with steady EBITDA-to-PAT conversion of 54%. - Reported PAT increased 56.7% due to a gain from divesting Pivot Path. - The company aims to maintain gross margins within 58-60% range. - Return on Capital Employed (ROCE) is expected to improve as recent investments mature. - Management focused on profitability and portfolio quality rather than growth at any cost for U.S.
From STAR's Q1 FY27 earnings-call transcript · updated 8 Sept 2026.
Revenue & Sales Performance
- Strides aims to grow its U.S. business from USD 285 million to USD 375 million by FY28, driven by five levers including OTC business, controlled substances, new product launches, specialty channels, and new partnerships.
- Controlled substances are expected to contribute significantly to growth following completion of past sales history demonstration (1.5 years demonstrated), with higher quota allocations anticipated from next cycles.
- Approximately 10 product launches are planned by March next year, focusing on higher-revenue potential products (USD 10-15 million each).
- Beyond FY28, growth is expected to be driven by advancements in three key domains—nasal sprays, transdermal patches, and thin films—with multiple filings and launches planned over next 12-18 months.
2 more points from STAR's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what STAR said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current capex is a combination of maintenance capex, R&D, and hard capex, totaling about INR 2.5 to 3 billion per year.
- No greenfield capex is planned at this point; focus remains on enhancing existing factories and investing in high-impact line items.
- Strategic investment includes the sale of majority stake in Pivot Path, with retained 20% interest, expected to contribute to PAT in the next 4-5 years.
- The company continues investments in new technology platforms like nasal sprays, transdermal patches, films, and controlled substances to support future growth.
2 more points from STAR's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what STAR said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from STAR's call on order book
Pro opens every point from 15K+ earnings calls
STAR — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.3K Cr, net profit ₹129 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Strides Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Sanjivani Paranteral Ltd (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Symbiotec Pharma (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Key concall takeaways from Symbiotec Pharmalab…
- Jubilant Pharmova Ltd (Q1 FY27)
2,229 Cr., up 17% YoY (Page 97) . Key concall takeaways from Jubilant Pharmova Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
- Beta Drugs Ltd (Q1 FY27)
Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Key concall takeaways from Beta Drugs Ltd's Q1 FY27…
Arthneeti Pro · Annual
STAR and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were STAR Q1 FY27 results?
Strides aims to grow its U.S. Strides Pharma Science expects steady revenue growth driven by diversified businesses, particularly strong momentum in Ex-US markets. - Operational EBIT margin was maintained around 18.2% despite geopolitical and cost pressures. - Operational PAT grew 8% year-on-year with steady EBITDA-to-PAT conversion of 54%. - Reported PAT increased 56.7% due to a gain from divesting Pivot Path. - The company aims to maintain gross margins within 58-60% range. - Return on Capital Employed (ROCE) is expected to improve as recent investments mature. - Management focused on profitability and portfolio quality rather than growth at any cost for U.S.
What is STAR share price analysis?
STAR currently shows a below-average growth signal. The stock trades at a P/E of 16.9 with a market cap of ₹9,767 Cr. Investors should review the full earnings analysis for detailed insights.
Is STAR planning capital expenditure?
Current capex is a combination of maintenance capex, R&D, and hard capex, totaling about INR 2.5 to 3 billion per year.
Keep STAR on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.